Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
MRS2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
MRS2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of MRS2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
MYLK3 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
MYLK3 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of MYLK3 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
MMGT1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
MMGT1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of MMGT1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
MOB2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
MOB2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of MOB2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
MARK2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
MARK2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of MARK2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
MEPE Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
MEPE Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of MEPE sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
MAP3K8 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
MAP3K8 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of MAP3K8 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
MARK4 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
MARK4 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of MARK4 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
MFSD2B Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
MFSD2B Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of MFSD2B sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
LRRC8B Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
LRRC8B Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of LRRC8B sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
LRRC8A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
LRRC8A Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of LRRC8A sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
LMAN2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
LMAN2 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of LMAN2 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →